Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury

JACC: Heart Failure

Volumn 3, Issue 1, 2015, Pages 30-39

  Ahmad, Tariq ^a   Wang, Teresa ^a   O'Brien, Emily C ^a   Samsky, Marc D ^a   Pura, John A ^a   Lokhnygina, Yuliya ^a   Rogers, Joseph G ^a   Hernandez, Adrian F ^a   Craig, Damian ^b   Bowles, Dawn E ^a   Milano, Carmelo A ^a   Shah, Svati H ^a,b   Januzzi, James L ^c   Felker, G Michael ^a   Patel, Chetan B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarkers; Heart failure; LVAD; Myocardial recovery

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPEPTIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN; SPIRONOLACTONE; ST2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DOWN REGULATION; FEMALE; FLUID BALANCE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE FIBROSIS; HEART MUSCLE OXYGEN CONSUMPTION; HEART STRESS; HUMAN; INFLAMMATION; KIDNEY INJURY; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; PULMONARY ARTERY OCCLUSION PRESSURE; THERAPY EFFECT; TREATMENT OUTCOME; BLOOD; EXERCISE TEST; FIBROSIS; FOLLOW UP; HEART ASSIST DEVICE; HEART MUSCLE; HOMEOSTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; BIOLOGICAL MARKERS; EXERCISE TEST; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HEART FAILURE; HEART-ASSIST DEVICES; HOMEOSTASIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84920267705     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.06.013     Document Type: Article

References (39)

1. Ahmad T., Patel C.B., Milano C.A., Rogers J.G. When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure. Circulation 2012, 125:2948-2955.
2. Birks E.J., George R.S., Hedger M., et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: aprospective study. Circulation 2011, 123:381-390.
3. Patel S.R., Saeed O., Murthy S., et al. Combining neurohormonal blockade with continuous-flow left ventricular assist device support for myocardial recovery: a single-arm prospective study. JHeart Lung Transplant 2013, 32:305-312.
4. Drakos S.G., Kfoury A.G., Stehlik J., et al. Bridge to recovery: understanding the disconnect between clinical and biological outcomes. Circulation 2012, 126:230-241.
5. Mann D.L., Barger P.M., Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target?. JAm Coll Cardiol 2012, 60:2465-2472.
6. Adler E., Silva Enciso J. Functional improvement after ventricular assist device implantation: is ventricular recovery more common than we thought?. JAm Coll Cardiol 2013, 61:1995-1997.
7. Ahmad T., Fiuzat M., Felker G.M., O'Connor C. Novel biomarkers in chronic heart failure. Nat Rev Cardiol 2012, 9:347-359.
8. Araujo J.P., Azevedo A., Lourenco P., Rocha-Goncalves F., Ferreira A., Bettencourt P. Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients withstable heart failure. Am J Cardiol 2006, 98:1248-1250.
9. Braunwald E. Heart failure. J Am Coll Cardiol HF 2013, 1:1-20.
10. Gullestad L., Ueland T., Kjekshus J., et al. Galectin-3 predicts response to statin therapy in theControlled Rosuvastatin Multinational Trial inHeart Failure (CORONA). Eur Heart J 2012, 33:2290-2296.
11. Bayes-Genis A., de Antonio M., Vila J., et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. JAm Coll Cardiol 2014, 63:158-166.
12. Felker G.M., Fiuzat M., Thompson V., et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail 2013, 6:1172-1179.
13. Miller W.L., Hartman K.A., Grill D.E., Struck J., Bergmann A., Jaffe A.S. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 2012, 98:389-394.
14. Neuhold S., Huelsmann M., Strunk G., et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction ofdeath at different stages ofthe disease. JAm Coll Cardiol 2008, 52:266-272.
15. van Deursen V.M., Damman K., Voors A.A., et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail 2014, 7:35-42.
16. Ahmad T., Fiuzat M., Mark D.B., et al. The effectsof exercise on cardiovascular biomarkers in patients with chronic heart failure. Am Heart J 2014, 167:193-202.
17. Halkar M., Tang W.H. Incorporating commonbiomarkers into the clinical management ofheart failure. Curr Heart Fail Rep 2013, 10:450-457.
18. Zilinski J.L., Shah R.V., Gaggin H.K., Gantzer M.L., Wang T.J., Januzzi J.L. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care 2012, 16:R135.
19. Ky B., French B., Levy W.C., et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012, 5:183-190.
20. Januzzi J.L., Rehman S.U., Mohammed A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. JAm Coll Cardiol 2011, 58:1881-1889.
21. Felker G.M., Fiuzat M., Shaw L.K., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012, 5:72-78.
22. Felker G.M., Fiuzat M., Thompson V., et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail 2013, 6:1172-1179.
23. Fenske W., Wanner C., Allolio B., et al. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. JAm Soc Nephrol 2011, 22:782-790.
24. Kempf T., von Haehling S., Peter T., et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. JAm Coll Cardiol 2007, 50:1054-1060.
25. Anand I.S., Latini R., Florea V.G., et al. C-reactiveprotein in heart failure: prognostic value and the effect of valsartan. Circulation 2005, 112:1428-1434.
26. Maisel A.S., Mueller C., Fitzgerald R., et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011, 13:846-851.
27. Wollert K.C., Kempf T., Peter T., et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007, 115:962-971.
28. Lok S.I., Winkens B., Goldschmeding R., et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012, 14:1249-1256.
29. Ambardekar A.V., Buttrick P.M. Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular effects. Circ Heart Fail 2011, 4:224-233.
30. Milting H., El Banayosy A., Kassner A., et al. The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricular assist device support reveals differences among device types. JHeart Lung Transplant 2001, 20:949-955.
31. Bruggink A.H., de Jonge N., van Oosterhout M.F., et al. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. JHeart Lung Transplant 2006, 25:174-180.
32. Milting H., Ellinghaus P., Seewald M., et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. JHeart Lung Transplant 2008, 27:589-596.
33. Masai T., Sawa Y., Ohtake S., et al. Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg 2002, 73:549-555.
34. Hasin T., Topilsky Y., Schirger J.A., et al. Changes in renal function after implantation of continuous-flow left ventricular assist devices. JAm Coll Cardiol 2012, 59:26-36.
35. Januzzi J.L., Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013, 127:500-507.
36. Gaggin H.K., Motiwala S., Bhardwaj A., Parks K.A., Januzzi J.L. Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure. Circ Heart Fail 2013, 6:1206-1213.
37. Motiwala S.R., Szymonifka J., Belcher A., et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 2013, 15:1157-1163.
38. Kato T.S., Chokshi A., Singh P., et al. Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. Circ Heart Fail 2011, 4:546-553.
39. Drakos S.G., Wever-Pinzon O., Selzman C.H., et al. Magnitude and time course of changes induced bycontinuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol 2013, 61:1985-1994.